Vitamin D supplementation: A pharmacologic perspective

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 13, Issue 6, 2010, Pages 677-684

  Boullata, Joseph I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

calcidiol; calciferol; calcitriol; cholecalciferol; ergocalciferol; vitamin D

Indexed keywords

COLECALCIFEROL; ERGOCALCIFEROL; PLACEBO;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENETIC POLYMORPHISM; HUMAN; HYPERCALCEMIA; NONHUMAN; REVIEW; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NUTRITION POLICY; NUTRITIONAL STATUS; POLYMORPHISM, GENETIC; VITAMIN D; VITAMINS;

EID: 78149245484     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32833de911     Document Type: Review

References (87)

1. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the U. S. population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008;88:1519-1527.
2. Yetley EA. Assessing the vitamin D status of the U. S. population. Am J Clin Nutr 2008;88:558S-564S.
3. Ceglia L. Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 2009;12:628-633.
4. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009;19:468-483.
5. Giovannucci E. Vitamin D and cardiovascular disease. Curr Atheroscler Rep 2009;11:456-461.
6. Peterlik M, Grant WB, Cross HS. Calcium, vitamin D and cancer. Anticancer Res 2009;29:3687-3698.
7. Tuohimaa P, Keisala T, Minasyan A, et al. Vitamin D, nervous system and aging. Psychoneuroendocrinol 2009;34:S278-S286.
8. Walker VP, Modlin RL. The vitamin D connection to pediatric infections and immune function. Pediatr Res 2009;65:106R-113R.
9. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010;95:471-478.
10. Hayes DP. Vitamin D and ageing. Biogerentol 2010;11:1-16.
11. Liu E, Meigs JB, Pittas AG, et al. Predicted 25-hydroxyvitamin D score and • incident type 2 diabetes in the Framingham Offspring Study. Am J Clin Nutr 2010;91:1627-1633. This cohort study evaluates the association between vitamin D status and type 2 diabetes.
12. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152:315-323.
13. Wang T-T, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1, 25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin (2 innate immune pathway defective in Crohn disease. J Biol Chem 2010;285:2227-2231.
14. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med 2009;122:793-802.
15. Bischoff-Ferrari H. Health effects of vitamin D. Dermatol Ther 2010;23:23-30.
16. Kubodera N. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidiol and doxercalciferol. Molecules 2009;14:3869-3880.
17. Choi M, Makishima M. Therapeutic applications for novel nonhypercalcemic vitamin D receptor ligands. Expert Opin Ther Patents 2009;19:593-606.
18. Wagner D, Sidhom G, Whiting SJ, et al. The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults. J Nutr 2008;138:1365-1371.
19. Armas L A G, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89:5387-5391.
20. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88(Suppl): 582S-586S.
21. Harris SS, Dawson-Hughes B. Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3. J Am Coll Nutr 2002;21:357-362.
22. Ilahi M, Armas L A G, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008;87:688-691.
23. Heaney RP, Armas L A G, Shary JR, et al. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008;87:1738-1742.
24. Stumpf WE. Drug localization and targeting with receptor microscopic autoradiography. J Pharmacol Toxicol Methods 2005;51:25-40.
25. Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspect Med 2008;29:433-452.
26. Sinotte M, Diorio C, Berube S, et al. Genetic polymorphisms of the vitamin D • binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009;89:634-640. This cross-sectional study evaluates the association of DBP polymorphisms with affinity to the protein.
27. Ray A, Swamy N, Ray R. Cross-talk among structural domains of human DBP upon binding 25-hydroxyvitamin D. Biochem Biophys Res Comm 2008;365:746-750.
28. Safadi FF, Thornton P, Magiera H, et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999;103:239-251.
29. Engelman CD, Fingerlin TE, Langefeld CD, et al. Genetic and environmental determinants of 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab 2008;93:3381-3388.
30. Willnow TE, Nykjaer A. Cellular uptake of steroid carrier proteins: mechanisms and implications. Mol Cell Endocrinol 2010;316:93-102.
31. Rowling MJ, Kemmis CM, Taffany DA, Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr 2006;136:2754-2759.
32. Compher CW, Badellino KO, Boullata JI. Vitamin D and the bariatric surgical patient: a review. Obes Surg 2008;18:220-224.
33. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008;88(Suppl): 491S-499S.
34. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004;29:664-673.
35. Lehmann B, Meurer M. Vitamin D metabolism. Derm Ther 2010;23:2-12.
36. Zhou C, Assem M, Tay JC, et al. Steroid andxenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116:1703-1712.
37. Goltzman D. Vitamin D action: lessons learned from genetic mouse models. Ann NY Acad Sci 2010;1192:145-152.
38. Liu N, Nguyen L, Chun RF, et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinol 2008;149:4799-4808.
39. 3 on CYP27B inhibition.
40. Janjetovic Z, Tuckey RC, Nguyen MN, et al. 20, 23-Dihydroxyvitamin D3, novel • P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes. J Cell Physiol 2010;223:36-48. This description of a novel vitamin D metabolite and its action in keratinocytes gives further insight into cell signaling.
41. De Luca HF. Vitamin D and the parenteral nutrition patient. Gastroenterol 2009;137:S79-S91.
42. Honzawa S, Yamamoto Y, Yamashita A, et al. The 2 (-(3-hydroxypropyl) group as an active motif in vitamin D3 analogues as agonists of the mutant vitamin D receptor (Arg274Leu). Bioorg Med Chem 2008;16:3002-3024.
43. Sicinska W, Rotkiewicz P. Structural changes in vitamin D receptor induced • by 20-epi-1 (, 25-(OH) 2D3: an insight from a computational analysis. J Steroid Biochem Mol Biol 2009;113:253-258. An analytical computational tool is used to evaluate VDR ligands' influence on the structure/function of the receptor.
44. Campbell FC, Xu H, El-Tanani M, et al. The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissuespecific growth control. Biochem Pharmacol 2010;79:1-9.
45. Liu PT, Krutzik SR, Modlin RL. Therapeutic implications of the TLR and VDR partnership. Trends Mol Med 2007;13:117-124.
46. Spirig R, Potapova I, Shaw-Boden J, et al. TLR2 and TLR4 agonists induce • production of the vasoactive peptide endothelin-1 by human dendritic cells. Mol Immunol 2009;46:3178-3182. A study describing the influence of vitamin D on production of endothelin-1 in dendritic cells.
47. Enioutina EY, Bareyan D, Daynes RA. TLR-induced local metabolism of • vitamin D3 plays an important role in the diversification of adaptive immune responses. J Immunol 2009;182:4296-4305. A group of studies examining the roles played by locally metabolized vitamin D in adaptive immunity.
48. Rosenblatt J, Bissonnette A, Ahmad R, et al. Immunomodulatory effects of • vitamin D: implications for GVHD. Bone Marrow Transplant 2010. doi: 10.1038/bmt.2009.366 [Epub ahead of print]. A study evaluating the effects of vitamin D on dendritic cells.
49. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-1773.
50. Bogunia-Kubik K, Middleton P, Norden J, et al. Association of vitamin D receptor polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Int J Immunogenet 2008;35:207-213.
51. Huhtakangas JA, Olivera CJ, Bishop JE, et al. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 (, 25 (OH) 2-vitamin D3 in vivo and in vitro. Mol Endocrinol 2004;18:2660-2671.
52. 3-MARRS expression and its subcellular distribution and signaling pathways.
53. Lou Y-R, Molnár F, Peräkylä M, et al. 25-Hydroxyvitamin D3 is an agonistic • vitamin D receptor ligand. J Steroid Biochem Mol Biol 2010;118:162-170. Study in animal model and various cell cultures of the direct gene regulatory properties of 25 (OH) D.
54. Hayes DP. Adverse effects of nutritional inadequacy and excess: a hormetic model. Am J Clin Nutr 2008;88(Suppl): 578S-581S.
55. Smith SM, Gardner KK, Locke J, Zwart SR. Vitamin D supplementation during • Antarctic winter. Am J Clin Nutr 2009;89:1092-1098. A prospective randomized double-blind study of the effectiveness of 5 months supplementation with vitamin D at three dosing levels.
56. Kimball SM, Ursell MR, O'Conner P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007;86:645-651.
57. Haderslev KV, Jeppesen PB, Sorensen HA, et al. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut 2003;52:653-658.
58. 3 in gastric bypass patients.
59. Boullata JI, Compher CW, Schiavone PA, et al. Oral vitamin D repletion in patients with parenteral nutrition-dependent intestinal failure. Nutr Clin Pract 2009;24:138.
60. Schleithoff SS, Zitterman A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a doubleblind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754-759.
61. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. Circ Heart Fail 2010;3:195-201.
62. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15:1113-1118.
63. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003;18:343-351.
64. Broe KE, Chen TC, Weinberg J, et al. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatric Soc 2007;55:234-239.
65. Pfeifer M, Begerow B, Minne HW, et al. Effects of a long-term vitamin D and • calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int 2009;20:315-322. A prospective randomized double-blind trial of calcium with or without vitamin Dfor 12 months in elderly patients followed for an additional 8 months to evaluate the effect on muscle function and falls.
66. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307-314.
67. Aloia JF, Patel M, Di Maano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr 2008;87:1952-1958.
68. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006;84:694-697.
69. Aksnes L, Aarskog D. Vitamin D metabolites in serum from hypoparathyroid patients treated with vitamin D2 and 1alpha-hydroxy vitamin D3 [abstract]. Pediatr Res 1981;15:78.
70. Vargas JH, Klein GI, Ament ME, et al. Metabolic bone disease of parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminum content. Am J Clin Nutr 1988;48:1070-1078.
71. Mastaglia SR, Mautalen CA, Parisi MS, Oliveri B. Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women. Eur J Clin Nutr 2006;60:681-687.
72. Tjellesen L, Hummer L, Christiansen C, Rødbro P. Serum concentration of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women. Bone Miner 1986;1:407-413.
73. Trang H, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998;68:854-858.
74. 3.
75. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008;93:677-681.
76. Biancuzzo RM, Young A, Bibuld D, et al. Fortification of orange juice with • vitamin D2 or vitamin D3 is as effective as an oral supplement in maintaining vitamin D status in adults. Am J Clin Nutr 2010;91:1621-1626. A study that compares the bioavailability of vitamin D from orange juice and supplements.
77. Holvik K, Madar AA, Meyer HE, et al. A randomized comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10jxg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults. Br J Nutr 2007;98:620-625.
78. Yetley EA, Brule D, Cheney MC, et al. Dietary reference intakes for vitamin D: justification for a review of the 1997 values. Am J Clin Nutr 2009;89:719-727.
79. Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Res 2009;29:3675-3684.
80. 3 to examine the value of loading doses.
81. Bolland MJ, Bacon CJ, Horne AM, et al. Vitamin D insufficiency and health • outcomes over 5 y in older women. Am J Clin Nutr 2010;91:82-89. An evaluation of vitamin D status and health outcomes in a cohort of older women. Raises the question of the value of universal supplementation.
82. Heaney RP. Vitamin D: criteria for safety and efficacy. Nutr Rev 2008;66(Suppl 2):S178-S181.
83. Hathcock JN, Shao A, Vieth R, Heaney RP. Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6-18.
84. Tai K, Need AG, Horowitz M, Chapman IM. Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition 2008;24:950-956.
85. Muindi JR, Johnson CS, Trump DL, et al. A phase I and pharmacokinetics • study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;65:33-40. A study of intravenous administration of calcitriol that includes a description of calcemic responses.
86. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated • patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. A study evaluating the influence of vitamin D on CYP3A substrate.
87. Chow E C Y, Sun H, Khan AA, et al. Effects of 1alpha, 25-dihydroxyvitamin D3 • on transporters and enzymes of the rat intestine and kidney in vivo. Biopharm Drug Dispos 2010;31:91-108. A study of the regulatory mechanisms of calcitriol on multiple transporters and enzymes via VDR.